Erythropoietin treatment is associated with a reduced incidence of moderate to severe bronchopulmonary dysplasia in preterm infants born at 23 to 32 weeks gestation

BACKGROUND: Advances in medical care have led to improved survival rates of extremely premature infants but the incidence of bronchopulmonary dysplasia (BPD) has not changed in the last two decades. Animal data suggests that erythropoietin treatment could ameliorate pulmonary vascular and alveolar development in neonatal models of BPD OBJECTIVE: To determine whether premature infants treated with erythropoietin (EPO) in …